P53 Expression in Sporadic Colorectal Carcinoma

Abstract

Objective:  To determine expression of p53 in colorectal carcinoma (CRC) tissues and to find the frequency of p53 over-expression in various stages and grades of tumor.

Methodology: A prospective observational design study was conducted at BMSI JPMC between January 2023 till October 2023, after obtaining approval from ethics review committee. Fifty-six patients of CRC were recruited and the tumor tissue was subjected to H&E staining. The extent of nuclear immunoreactivity of p53 was scored from 0-3. The intensity was score from mild to strong, with score zero for no intensity. The results of immunohistochemistry were used to determine frequency of p53 over-expression with Astler and Coller grading and staging system and TNM staging.

Results: There were 30 cases (53.5 %) cases which showed p53 over-expression. The Astler and Coller grading and staging system showed that the majority of cases were in stage B2 (44.6%) followed by C2. As compared to other stages, TNM stage 3 showed higher frequency of p53 overexpression.

Conclusion: there is high frequency of p53 over-expression which highlights its significance. The over-expression has been found in higher stage and grade which indicates that it may form a key molecular event that may act as a prognostic as well as possible therapeutic marker.